| Literature DB >> 33732903 |
Lucimari Teixeira Essenfelder1, Anderson Albino Gomes1, Jefferson Luis Meirelles Coimbra2, Marcelo Alves Moreira2, Sandra Maria Ferraz3, David José Miquelluti2, Gustavo Felippe da Silva1, Maria de Lourdes Borba Magalhães1.
Abstract
β-Glucosidases are enzymes present in all living organisms, playing a pivotal role in diverse biological processes. These enzymes cleave β-glycosidic bonds between carbohydrates, or between a carbohydrate and a non-carbohydrate moiety, which may result in the liberation of volatile aglycones. Released compounds execute diverse physiological roles, while the industry takes advantage of exogenously added β-glucosidases for aroma enrichment during food and beverage production. β-Glucosidase enzymatic activity has been reported in human saliva and given the fact that these enzymes are involved in aroma release, we investigated here the correlation between β-glucosidase activity in human saliva and the occurrence of halitosis. Measurement of salivary enzyme activity of 48 volunteers was performed using p-nitrophenyl-β-d-glucopyranoside as substrate. Each volunteer was clinically evaluated by a dental surgeon and clinical and laboratorial data were statistically analyzed. Gas-chromatography of saliva headspace allowed the analysis of the direct role of exogenous β-glucosidase on aromatic /volatile profile of saliva samples. The data demonstrated a positive correlation between halitosis and enzymatic activity, suggesting that the enzyme exerts a direct role in the occurrence of bad breath. Gas-chromatography analysis demonstrated that exogenously added enzyme led to the alteration of volatile organic content, confirming a direct contribution of β-glucosidase activity on saliva volatile compounds release. Although halitosis is a multifactorial condition, the complete understanding of all governing factors may allow the development of more effective treatment strategies. Such studies may pave the way to the use of β-glucosidase inhibitors for halitosis clinical management.Entities:
Keywords: Biofilm; Halitosis; Oral health; Saliva; β-Glucosidase
Year: 2021 PMID: 33732903 PMCID: PMC7941027 DOI: 10.1016/j.bbrep.2021.100965
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Analysis of evaluated clinical conditions. Forty-eight volunteers were examined to determine the presence of specific clinical conditions. Of these, only eight did not present any clinical condition. Of the remaining 40 volunteers, the majority presented an association of two or more clinical conditions.
| Clinical condition | % volunteer | % Halitosis | % Additional clinical conditions | N |
|---|---|---|---|---|
| Visible dental biofilm | 52.1% | 80% | 88% | 25 |
| Halitosis | 66.7% | N/A | 96.9% | 32 |
| Calculus | 29.2% | 71.4% | 92.9% | 14 |
| Tongue Coating | 37.5% | 83.3% | 72.2% | 18 |
| Gingivitis | 56.3% | 81.5% | 96.3% | 27 |
| Caries | 6.3% | 66.7% | 100% | 3 |
| Periodontitis | 4.2% | 50% | 100% | 2 |
| No clinical condition | 16.7% | 12.5% | N/A | 8 |
| Total of volunteers | 48 | |||
N total number of volunteers presenting clinical condition.
Percentage of the volunteers presenting the specified clinical condition.
Percentage of the volunteers with the specific condition that presented halitosis.
Percentage of volunteers that presented additional clinical conditions.
Fig. 1Mean of β-glucosidase activity in fresh saliva samples. 40 (83.3%) of 48 volunteers showed positive β-glucosidase activity in fresh whole saliva samples. Positive activity was considered for samples with V > 0.07 nmol/g/min. The volunteers in this group had an average of β-glucosidase activity triplicates ranging from v = 0.075 nmol /g /min to 1.08 nmol /g /min.
Mean of β-glucosidase activity in fresh saliva samples in the presence or absence of clinical conditions. Volunteers presenting halitosis, visible dental biofilm and gingivitis presented higher enzymatic activity in saliva compared to volunteers without this clinical condition. Interestingly the mean of β-glucosidase activity among halitosis-patients was two-fold higher compared to β-glucosidase activity in halitosis-absent patients.
| Clinical sign | N | Mean β-glucosidase activity | p-value |
|---|---|---|---|
| Halitosis | |||
| + | 32 | 0.294 ± 0.03 nmol/g/min | 0.0003 |
| – | 16 | ||
| Biofilm | |||
| + | 25 | 0.284 ± 0.04 nmol/g/min | 0.0390 |
| – | 23 | ||
| Gingivitis | |||
| + | 27 | 0.281 ± 0.04 nmol/g/min | 0.0585 |
| – | 21 | ||
| Tongue coating | |||
| + | 18 | 0.213 ± 0.02 nmol/g/min | 0.6624 |
| – | 30 | ||
| Total of volunteers | 48 | ||
+ Positive cases for the specified clinical condition.
- Negative cases for the specified clinical condition.
N Total of volunteers with or without the clinical condition.
Mean of triplicates after enzymatic assays ± standard error.
Fig. 2Analysis of β-glycosidase activity versus halitosis score. Panel A: Halitosis score was determined based on the level of odor intensity (0,1, 2 and 3) determined by the portable sulfur monitor (Tanita Breath Checker) or by the organoleptic test (Panel B). The enzymatic activity of volunteers that did not present halitosis (score zero) are represented in the dashed red boxes. Symbols represent the mean of salivary enzymatic activity of each volunteer and error bars represent the standard deviation. Measurements were performed in triplicates. The black diagonal line is the regression line fit. Panel A R2 = 0.099, Panel B R2 = 0.065. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Statistical analysis. Residual deviances and AIC values of adjusted models. Only the main effects of visible dental biofilm, tongue coating and enzymatic activity were significant (P <0.05).
| Model | d.f. | Null deviances | Residual deviances | d.f.residual | p-value | AIC |
|---|---|---|---|---|---|---|
| Null | 45 | 59.44 | 1 | 61.4 | ||
| X1 | 44 | 55.06 | 4.38 | 1 | 0.036 * | 59.06 |
| X2|X1 | 43 | 50.56 | 4.50 | 1 | 0.034 * | 56.56 |
| X3|X1, X2 | 42 | 44.15 | 6.41 | 1 | 0.011 * | 52.15 |
| Model | ||||||
| β0- Constant | -1.883 | 0.837 | ||||
| β1- X1 | 1.026 | 0.755 | ||||
| β2- X2 | 1.520 | 0.815 | ||||
| β3- X3 | 8.196 | 3.733 | ||||
AIC Akaike Information Criterion; d.f degree of freedom; X1presence /absence of visible dental biofilm; X2 presence /absence of tongue coating; X3salivary β-glucosidase activity.
Fig. 3Headspace Gas Chromatography of saliva samples. The figure shows the overlapped VOC profile of β-glucosidase treated saliva sample (black trace) and control saliva sample (red trace) from one volunteer. The zoomed in region presents several VOC peaks in the treated sample, which are absent in the control sample. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Volatile compounds released upon action of exogenousβ-glucosidase in human saliva samples. Analysis of volatile headspace compounds of centrifuged saliva samples by gas-chomatography-Mass Spectometry (GC-MS) after overnight incubation with active β-glucosidase from Bacillus polymyxa. Analysis of salivary samples from six patients identified 17 different volatile compounds. Control: Samples containing heat inactivated β-glucosidases purified from B. polymyxa.
| Volatile compounds | Sample |
|---|---|
| 4 | |
| 4 | |
| 4 | |
| 4 | |
| 4, 12 | |
| 12 | |
| 12 | |
| 12, 10 | |
| 15 | |
| 15 | |
| 10 | |
| 10 | |
| 10 | |
| 10 | |
| 11 | |
| 11 | |
| 8 |
Sample number.